Product Images Fulvestrant

The text shows the proportion of patients who were progression-free during the study while using Fulvestrant doses 250 mg and 500 mg. The study included an ITT population, with 374 patients using Fulvestrant 250 mg and 362 patients using Fulvestrant 500 mg. The number at risk is also shown over a period of 36 months. The data presented is not completely readable as it seems to have formatting issues.*

This is a graph of the survival rate of patients treated with two dosages of Fulvestrant. The x-axis indicates the time in months, while the y-axis displays the survival rate. The blue line shows the survival rate of patients treated with Fulvestrant 500mg, whereas the green line shows the survival rate of those treated with Fulvestrant 250mg. Tick marks are used to indicate observations that were censored. The note at the bottom of the graph suggests that the study's findings are not statistically significant as no adjustments were made for multiplicity.*

This is a table showing the results of a study on the impact of drugs Fulvestrant, Palbociclib, and Placebo on a certain number of patients. There is information on the time and the number of patients at risk for different stages.*

The given text is a statistical table represents Censored observations for Fulvestrant plus Abemaciclib (N=446) group and Fulvestrant plus Placebo (N=223) group. The table contains information regarding Pationts st riskc time (in months) and number of observations for each group at that time point. The table shows the number of patients at risk for each group during the follow-up period. A comparison can be made to determine the efficacy of the two treatments.*

The text is a graph showing the censoring times and number of patients still at risk for two treatments - Fulvestrant + Ribociclib and Fulvestrant + Placebo. The graph shows data points at 2-month intervals up to 38 months, and the number of patients still at risk for each treatment at each interval. There is no additional information available.*

The text describes a comparison study of two medications, Fulvestrant and palbociclib, versus Fulvestrant and placebo, in terms of overall survival probability over a period of 54 months. The data includes the number of patients at risk at certain time points.*

This appears to be a graph or chart showing observation results for two breast cancer treatments - "Fulvestrant plus Abemaciclib" and "Fulvestrant plus Placebo". The graph tracks the number of patients over time (in months) and displays the number of patients who remain in the trial at each point in time. There were 446 patients in the Fulvestrant plus Abemaciclib group and 223 in the Fulvestrant plus Placebo group. Additionally, there were 100 censored observations. No other information is given.*

This is a survival plot that compares two treatments (Fulvestrant+Ribociclib and Fulvestrant+Placebo) to treat a certain condition in a group of 484 and 242 patients, respectively, over a period of 26 months. The plot shows the event-free probability (percentage of patients who have not experienced the event of interest) over time, with the number of patients still at risk at each time point displayed on the x-axis. The line for Fulvestrant+Ribociclib shows a higher event-free probability compared to Fulvestrant+Placebo throughout the study period, suggesting that the former treatment is more effective.*